Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer | Advanced Pancreatic Cancers | Recruiting | Phase 1 | 2025-04-10 | NCT06760364 | |
| A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 | 2025-04-06 | NCT06914037 | |
| A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 1 | 2024-12-12 | NCT06730659 | |
| A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors | Mesothelin Positive Tumors | Recruiting | Not applicable | 2024-12-04 | NCT06717022 |